ZUG, Switzerland–(BUSINESS WIRE)–#AdvancingDermatology–Galderma: Galderma delivered strong performance Galderma delivered at the top end of its 2022 revenue guidance with 13.9% year-on-year net sales growth on a constant currency basis at 3,760 M USD and delivered above its 2022 profitability guidance with 14.5% Core EBITDA year-on-year growth on a constant currency basis at 791 M USD … [Read more…]
— Data presented at the North American Neuro-Ophthalmology Society (NANOS) Annual Meeting on March 11-16 in Orlando — DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients with DON, the majority of whom had not previously responded to other treatments. DON … [Read more…]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of these assets are not restricted by the … [Read more…]
— First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1 — Company expects DAYBUE to be available by the end of April, 2023 — Rare Pediatric Disease Priority Review Voucher granted in connection with approval — Conference call and webcast to be held … [Read more…]
SAN FRANCISCO–(BUSINESS WIRE)–Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS), the leading health and wellness platform, is aware of the current actions taken by the Federal Deposit Insurance Corporation with respect to Silicon Valley Bank (“SVB”). The Company has limited cash exposure resulting from the liquidity concerns at SVB. The … [Read more…]
LOS ANGELES–(BUSINESS WIRE)–#COVID19–AIDS Healthcare Foundation has repeatedly called for the depoliticization of the investigation into the origins of SARS-CoV-2 and for all reasonable hypotheses to be studied. Ahead of the third anniversary of the World Health Organization belatedly declaring COVID-19 a pandemic on March 11, 2020, there is renewed debate around the Wuhan lab leak … [Read more…]
MISSISSAUGA, Ontario–(BUSINESS WIRE)–Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“Miravo” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced arrangement (the “Arrangement”) with Searchlight Pharma Inc. (the “Purchaser”). The Arrangement is expected to close on … [Read more…]
LOS ANGELES–(BUSINESS WIRE)–#AfricanUnion–The African Union is taking steps to bring online the African Medicines Agency (AMA), a regulatory body designed to harmonize the approval of medicines across the continent. When fully operational, the AMA should speed up and simplify what is currently a lengthy drug registration process involving a patchwork of national regulators. AIDS Healthcare … [Read more…]
HOUSTON–(BUSINESS WIRE)–#CART—Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 … [Read more…]
-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -FDA clearance granted for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008)- -$327.0 million in year-end cash and cash equivalents and short-term investments- SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies … [Read more…]
